14-3-3 γ-isoform detection distinguishes sporadic Creutzfeldt-Jakob disease from other dementias

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 1, 2005, Pages 100-102

  Van Everbroeck, B R J ^a   Boons, J ^a   Cros, P ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CG31; ISOPROTEIN; POLYCLONAL ANTISERUM; POLYCLONAL ANTISERUM SC 731; PROTEIN 14 3 3; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DEMENTIA; DIFFERENTIAL DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; WESTERN BLOTTING;

EID: 10944259151     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.032037     Document Type: Article

References (18)

1. Masters CL, Harris JO, Gajdusek DC, et al. Creutzfeldt-Jakob disease: patterns of worldwide occurrence and the significance of familial and sporadic clustering. Ann Neurol 1979;5:177-88.
2. Zeidler M. 14-3-3 cerebrospinal fluid protein and Creutzfeldt-Jakob disease. Ann Neurol 2000;47:683-4.
3. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-15.
4. Van Everbroeck B, Quoilin S, Boons J, et al. A prospective study of CSF markers in 250 patients with passible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2003;74:1210-14.
5. Sanchez-Valle R, Saiz A, Graus F. 14-3-3 Protein isoforms and atypical patterns of the 14-3-3 assay in the diagnosis of Creutzfeldt-Jakob disease. Neurosci Lett 2002;320:69-72.
6. Peoc'h K, Schroder HC, Laplanche J, et al. Determination of 14-3-3 protein levels in cerebrospinal fluid from Creutzfeldt-Jakob patients by a highly sensitive capture assay. Neurosci Lett 2001;301:167-70.
7. Green AJ. Use of 14-3-3 in the diagnosis of Creutzfeldt-Jakob disease. Biochem Soc Trans 2002;30:382-6.
8. Beaudry P, Cohen P, Brandel JP, et al. 14-3-3 protein, neuron-specific enolase, and S-100 protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Dement Geriatr Cogn Disord 1999;10:40-6.
9. Chapman T, McKeel DW, Morris JC. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:1396-7.
10. Burkhard PR, Sanchez JC, Landis T, et al. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 2001;56:1528-33.
11. Zerr I, Poser S. Clinical diagnosis and differential diagnosis of GD and vCJD. With special emphasis on laboratory tests. APMIS 2002;110:88-98.
12. Green AJ. Cerebrospinal fluid brain-derived proteins in the diagnosis of Alzheimer's disease and Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol 2002;28:427-40.
13. Wiltfang J, Otto M, Baxter HC, et al. Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem 1999;73:2485-90.
14. Van Everbroeck B, Green AJ, Pals P, et al. Decreased levels of amyloid-beta 1-42 in cerebrospinal fluid of Creutzfeldt-Jakob disease patients. J Alzheimer's Dis 1999;1:419-24.
15. Van Everbroeck B, Dobbeleir I, De Waele M, et al. Differential diagnosis of 201 possible Creutzfeldt-Jakob disease patients. J Neurol 2004;251:298-304.
16. Aksamit AJ, Preissner CM, Homburger HA. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 2001;57:728-30.
17. Tyler JW, Lakritz J, Weaver D, et al. The 14-3-3 cerebrospinal fluid immunoassay lacks utility in the diagnosis of clinical scrapie. J Vet Diagn Invest 2001;13:537-9.
18. Otto M, Esselmann H, Schulz-Shaeffer W, et al. Decreased beta-amyloid 1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 2000;54:1099-102.